Dr. Motesharei is a seasoned biopharmaceutical business development executive with a global network and a proven deal track record, having completed over 100 transactions across licensing, mergers and acquisitions, financings, and strategic partnerships. He has held senior corporate development, licensing, and investor relations leadership roles at Madrigal Pharmaceuticals, Formation Bio, Akcea Therapeutics, Merck KGaA, Dyax, and Genfit.
Most recently, prior to joining Formation Bio, Dr. Motesharei led Business Development and Investor Relations at Madrigal Pharmaceuticals, where he played a key role in raising over $1 billion in capital, supporting the FDA approval of Rezdiffra®, the first approved therapy for NASH/MASH, and helping drive a market capitalization increase from approximately $800 million to over $7 billion. Earlier in his career, he partnered closely with the management teams at Genfit and Dyax to reposition Genfit’s lead program from atherosclerosis to NASH—contributing to a market capitalization increase from approximately $110 million to over $1.2 billion—and supported the development of Takhzyro®, Dyax’s next-generation hereditary angioedema therapy, which ultimately led to Dyax’s $6.5 billion acquisition by Shire, up from an initial market capitalization of approximately $120 million.
Dr. Motesharei holds a Ph.D. in Organic Chemistry from the University of California, Los Angeles, a B.A. in Chemistry from Colorado College, and completed his NIH postdoctoral fellowship at The Scripps Research Institute.
Back to Team